Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer

Lignende værker

• Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients
  af: Liu, Lin L., et al.
  Udgivet: (2015)
• Evolution of resistance to anti-cancer therapy during general dosing schedules
  af: Foo, Jasmine, et al.
  Udgivet: (2009)
• Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
  af: Pao, William, et al.
  Udgivet: (2010)
• Evolution of acquired resistance to anti-cancer therapy
  af: Foo, Jasmine, et al.
  Udgivet: (2014)
• Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling
  af: Chmielecki, Juliann, et al.
  Udgivet: (2011)